Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 8/20 | 0.62 |
| ▸ | PYGL | P06737 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.51 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604249 | 0.93 | POLB (0.54) | PYGMPYGL | |
| SCHEMBL4604342 | 0.86 | KDM4E (0.49) | PYGMPYGL | |
| SCHEMBL4603669 | 0.86 | ALDH1A1 (0.53) | PYGMSMN1; SMN2MEN1KMT2ASERPINE1 | |
| SCHEMBL4606880 | 0.86 | KMT2A (0.57) | PYGMPYGLSMN1; SMN2MAPTMEN1 | |
| SCHEMBL4604961 | 0.85 | ALDH1A1 (0.48) | PYGMPYGLSMN1; SMN2MAPTMEN1 | |
| SCHEMBL4606539 | 0.84 | MTNR1B (0.50) | PYGMPYGL | |
| SCHEMBL6431208 | 0.83 | PYGL (0.80) | PYGMPYGL | |
| SCHEMBL4605135 | 0.82 | KDM4E (0.49) | PYGMSMN1; SMN2MAPTMAPK1AHR | |
| SCHEMBL4606525 | 0.82 | CTSV (0.47) | PYGMPYGLSMN1; SMN2MAPTMEN1 | |
| SCHEMBL6430909 | 0.81 | PYGM (0.67) | PYGMPYGLSMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720825-B1 | ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS | ACTIVE BIOTECH AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-7074831-B2 | Compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | MALT1, TPMT, FUCA1 | PYGM 1086/4885PYGL 22/4885SMN1; SMN2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.